Filing Analysis
TriSalus Life Sciences, Inc. filed an 8-K to announce the release of its financial results for the second quarter ended June 30, 2026.
📋 Key Facts
- The filing is a standard announcement of Q2 2026 financial results.
- Report date: August 6, 2026.
- Reporting period: Second Quarter ended June 30, 2026.
TriSalus Life Sciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 14, 2026. Stockholders elected two directors, ratified the company's independent auditor, and approved executive compensation matters.
📋 Key Facts
- A total of 41,728,676 shares (67.9% of outstanding common stock) were represented at the meeting.
- Mary Szela and Gary Gordon were elected as directors to serve three-year terms expiring in 2029.
- Grant Thornton, LLP was ratified as the independent registered accounting firm for the fiscal year ending December 31, 2026.
- Stockholders approved a three-year frequency for future advisory votes on executive compensation.
- The advisory vote on the compensation of named executive officers was approved.
TriSalus Life Sciences, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- The report was filed on May 12, 2026.
- The financial results pertain to the fiscal quarter ended March 31, 2026.
- The filing was submitted under Item 2.02 (Results of Operations and Financial Condition).
- The report was signed by David Patience, Chief Financial Officer.
TriSalus Life Sciences announced the retirement of Jodi Devlin, Chief of Clinical Operations, effective October 1, 2026. The company also reaffirmed the upcoming appointment of Dr. Richard Marshall as Chief Medical Officer, effective June 29, 2026.
📋 Key Facts
- Jodi Devlin provided notice of retirement on April 24, 2026.
- The retirement of the Chief of Clinical Operations is effective October 1, 2026.
- Dr. Richard Marshall will assume the role of Chief Medical Officer on June 29, 2026.
- The filing was made under Item 5.02 of Form 8-K.
TriSalus Life Sciences, Inc. has appointed Dr. Richard Marshall as its new Chief Medical Officer, effective June 29, 2026. The appointment includes a comprehensive compensation package featuring a $525,000 base salary and significant equity incentives.
📋 Key Facts
- Dr. Richard Marshall appointed as Chief Medical Officer (CMO) starting June 29, 2026.
- Annual base salary is set at $525,000 with a $250,000 sign-on bonus.
- Eligible for an annual bonus of up to 50% of base salary ($262,500) based on milestones.
- Proposed equity award of 120,000 stock options and 60,000 restricted stock units (RSUs).
- No related-party transactions were reported in connection with the appointment.
TriSalus Life Sciences, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The disclosure was made via a press release on March 5, 2026, and furnished under Item 2.02.
📋 Key Facts
- The company reported financial results for the fiscal year and quarter ended December 31, 2025.
- The report was filed on March 5, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was included as Exhibit 99.1.
- The filing was signed by David Patience, Chief Financial Officer.
TriSalus Life Sciences announced a public offering of 9,756,100 shares of common stock at $4.10 per share, with an underwriting agreement through Lake Street Capital Markets. Net proceeds are expected to be approximately $37.0 million (or $42.64 million with full over-allotment exercise), intended for general corporate purposes. The offering includes a 90-day lock-up on officers, directors, and the company.
🚩 Red Flags
- Significant dilution: 9.76M new shares (plus potential 1.46M over-allotment) will materially dilute existing shareholders
- Offering price of $4.10 suggests low share price territory, common in micro-cap dilutive financings
- Vague use of proceeds — 'general corporate purposes' including working capital and G&A suggests potential cash burn concerns
- No specific growth initiatives or milestones cited for use of proceeds, raising questions about cash runway
- Lake Street Capital Markets as sole bookrunner — a smaller, micro-cap-focused underwriter, not a top-tier bank
- Multiple 8-K items in a single filing (1.01, 8.01, 9.01)
📋 Key Facts
- Offering of 9,756,100 shares at $4.10 per share public offering price
- 30-day over-allotment option for up to 1,463,415 additional shares
- Net proceeds expected ~$37.0M (no over-allotment) or ~$42.64M (full over-allotment)
- Underwriter discount of 6.0% per share; LSCM expense reimbursement capped at $125,000
- 90-day lock-up period for the company, officers, directors, and a certain securityholder
- Offering conducted under shelf registration on Form S-3 (File No. 333-291509), declared effective December 4, 2025
- Expected closing date on or about February 23, 2026
- Lead underwriter: Lake Street Capital Markets, LLC
- Proceeds designated for general corporate purposes including capex, working capital, and G&A
- Filed by CFO David Patience on February 20, 2026
TriSalus Life Sciences, Inc. announced the immediate resignation of Board member Dr. Arjun “JJ” Desai and the appointment of Michael P. Stansky to the Board, effective February 4, 2026.
📋 Key Facts
- Dr. Arjun 'JJ' Desai resigned from the Board effective February 3, 2026.
- The company stated Dr. Desai's resignation was not due to any disagreement regarding operations, policies, or practices.
- Michael P. Stansky appointed to the Board effective February 4, 2026.
- Mr. Stansky will serve on the Audit, Compensation, and Science and Technology Committees.
- No related party transactions were reported for the new director.
TriSalus Life Sciences, Inc. issued an 8-K to announce preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, along with revenue guidance for 2026.
📋 Key Facts
- Announced preliminary unaudited financial results for Q4 and FY 2025 on January 12, 2026.
- Provided revenue guidance for the fiscal year 2026.
- The filing includes a press release (Exhibit 99.1) containing detailed financial data.
TriSalus Life Sciences, Inc. issued an 8-K to announce its quarterly business update and financial results for the period ending September 30, 2025.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) containing business and financial updates.
- Company is an emerging growth company.
TriSalus Life Sciences, Inc. announced the resignation of Sean Murphy from the Board of Directors and the Science and Technology Committee, effective September 30, 2025.
🚩 Red Flags
- Departure of a board member involved in the 'Science and Technology Committee' can sometimes signal shifts in R&D direction, though no disagreement was cited.
📋 Key Facts
- Sean Murphy resigned from the Board of Directors on September 30, 2025.
- Resignation includes his position on the Science and Technology Committee.
- The resignation is stated to not be a result of any disagreement with the Company regarding operations, policies, or practices.
TriSalus Life Sciences, Inc. announced compensation adjustments for its Chief Financial Officer, David Patience, including a base salary increase and the granting of performance-based stock options.
🚩 Red Flags
- None identified; this is a standard compensatory adjustment filing.
📋 Key Facts
- Effective immediately (August 25, 2025), CFO David Patience's annual base salary increased from $450,000 to $550,000.
- On August 28, 2025, the Compensation Committee approved a grant of 249,899 stock options to Mr. Patience.
- Option exercise price is set at $5.11 per share.
- Options vest contingent on achieving/exceeding $75 million in revenue over any 12 consecutive months ending by December 31, 2027.
TriSalus Life Sciences, Inc. filed an 8-K to announce its quarterly business update and financial results for the period ending June 30, 2025.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) detailing business and financial updates.
- Company is an emerging growth company.
TriSalus Life Sciences successfully completed an Offer and Consent Solicitation, resulting in 98.82% of Series A Convertible Preferred Stock being tendered for exchange into common stock. The company also amended its Certificate of Designations to allow for the mandatory conversion of remaining preferred shares.
🚩 Red Flags
- Significant dilution risk: The exchange ratio is based on a liquidation preference and accrued dividends divided by $4.00, which could result in substantial issuance of new common equity.
- Concentrated control/exit: Over 98% of preferred holders participated, indicating a massive restructuring of the company's capital stack.
📋 Key Facts
- The Offer and Consent Solicitation expired on July 23, 2025.
- 3,551,502 shares of Preferred Stock (approx. 98.82% of outstanding) were validly tendered.
- The company expects to complete the exchange/settlement on or before August 1, 2025.
- A Preferred Stock Amendment was filed with the Secretary of State of Delaware on July 24, 2025.
- The amendment allows the company to require conversion of all outstanding preferred shares into common stock upon closing.
TriSalus Life Sciences has launched an exchange offer and consent solicitation to convert outstanding Preferred Stock into Common Stock. The company aims to amend its Certificate of Designations to facilitate this restructuring, with 55% of preferred holders already committed via tender and support agreements.
🚩 Red Flags
- Significant potential dilution: The company is offering up to 11.86 million new shares of common stock.
- Capital restructuring: This type of move often indicates a need to clean up the cap table or address preferred liquidation preferences that may impede future financing.
- Complexity of terms: The conversion ratio involves complex calculations including accrued dividends through a future date (August 2027).
📋 Key Facts
- Commenced an exchange offer for Preferred Stock in exchange for up to 11,860,206 shares of Common Stock.
- The exchange ratio is based on the sum of Liquidation Preference and Accrued Dividends (through August 10, 2027) divided by $4.00 per share.
- Includes a Consent Solicitation to amend the Certificate of Designations regarding conversion terms.
- Approximately 55% of outstanding Preferred Stock holders have already agreed to tender and support the amendment via Tender and Support Agreements.
- The offer is scheduled to expire on July 23, 2025 (or an extension thereof).
- A registration statement on Form S-4 was filed simultaneously with this announcement.
TriSalus Life Sciences, Inc. held its Annual Meeting of Shareholders on June 12, 2025. The company successfully elected two directors and ratified the appointment of Grant Thornton, LLP as its independent accounting firm.
📋 Key Facts
- Annual Meeting held on June 12, 2025.
- Quorum was established with 26,482,799 shares (73.2% of outstanding shares) represented.
- Mats Wahlström and David J. Matlin were elected to the Board of Directors for three-year terms expiring in 2028.
- Grant Thornton, LLP was ratified as the independent registered accounting firm for the year 2025.
TriSalus Life Sciences announced the resignation of CFO James Young effective May 30, 2025, and the appointment of David Patience as his successor. Mr. Young's departure includes a severance package consisting of six months' salary and continued equity vesting through May 2026.
🚩 Red Flags
- Sudden departure of a key executive (CFO) can sometimes signal internal friction or financial concerns, though 'personal reasons' is the stated cause.
- Significant cash outflow for severance (6 months salary) during a transition period.
📋 Key Facts
- CFO James Young resigned for personal reasons effective May 30, 2025.
- Severance for Mr. Young includes 6 months of annual salary and equity vesting until May 31, 2026.
- David Patience hired as new CFO; start date expected July 1, 2025.
- New CFO compensation: $450,000 base salary, $159,000 sign-on bonus, and potential for a performance equity grant in Q1 2026.
- Proposed stock option grant for new CFO equal to 1% of issued and outstanding common stock.
TriSalus Life Sciences, Inc. filed an 8-K to announce its quarterly financial results and provide a business update for the period ended March 31, 2025.
📋 Key Facts
- The filing is a routine announcement of quarterly financial results (Item 2.02).
- Reporting period: Quarter ended March 31, 2025.
- Date of report: May 15, 2025.
- The company is an emerging growth company.
TriSalus Life Sciences entered into a $22 million private placement of 5.5 million common shares at $4.00 per share and simultaneously announced an exchange offer to convert Series A Preferred Stock into common stock via a support agreement with holders of 55% of the preferred shares.
🚩 Red Flags
- Significant dilution: Issuance of 5.5 million new shares at $4.00 per share.
- Aggressive restructuring of capital structure: The exchange offer significantly reduces the liquidation preference for preferred holders (from $10.00 to a ratio based on $4.00) and removes anti-dilution protections (price reset provision).
- Liquidated damages clause in registration rights agreement indicating high pressure to meet SEC timelines.
📋 Key Facts
- Private Placement: Sale of 5,500,000 shares at $4.00 per share, totaling approximately $22 million in gross proceeds.
- Registration Rights: Company must file a registration statement for the new shares within 30 days and faces liquidated damages (1% per 30-day period) if deadlines are missed.
- Preferred Stock Exchange Offer: Offering to exchange Series A Preferred Stock for common stock at a conversion ratio based on $4.00/share (vs. current liquidation preference of $10.00).
- Amendment Proposal: Seeking to eliminate the downward conversion price reset provision scheduled for July 2027.
- Support Agreement: Holders of ~55% of Series A Preferred Stock have agreed to tender their shares and vote in favor of the amendments.
- Revenue Growth: Preliminary Q1 2025 revenue reported at $9.2 million, a 42% increase YoY.
TriSalus Life Sciences, Inc. announced the immediate resignation of George Kelly Martin from the Board of Directors and his roles on the Audit and Compensation Committees effective April 20, 2025.
🚩 Red Flags
- Immediate departure of a director serving on both Audit and Compensation committees can sometimes signal internal friction, though the filing explicitly denies disagreement.
📋 Key Facts
- George Kelly Martin resigned from the Board of Directors, Audit Committee, and Compensation Committee.
- Resignation was effective immediately as of April 20, 2025.
- The company stated the resignation is not due to any disagreement regarding operations, policies, or practices.
TriSalus Life Sciences, Inc. announced the immediate resignation of Liselotte Hyveled from her positions on the Board of Directors and two key committees.
🚩 Red Flags
- Immediate departure of a board member can sometimes signal internal friction, though the filing explicitly denies this.
📋 Key Facts
- Liselotte Hyveled resigned effective April 16, 2025.
- Resignation includes roles as a member of the Board, the Nominating and Corporate Governance Committee, and the Science and Technology Committee.
- The company explicitly stated the resignation was not due to any disagreement regarding operations, policies, or practices.
TriSalus Life Sciences, Inc. issued a press release on March 27, 2025, providing a business update and announcing its unaudited financial results for the fiscal year ended December 31, 2024.
🚩 Red Flags
- Financial information is unaudited and subject to change
📋 Key Facts
- Report date: March 27, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes a business update and financial results via Exhibit 99.1
- Financial information provided is unaudited and subject to change
TriSalus Life Sciences, Inc. announced that Sean Murphy will step down from his role as an officer and employee effective February 28, 2025. He will remain on the Company's Board of Directors.
📋 Key Facts
- Sean Murphy notified the company of his intent to step down as an officer and employee.
- Effective date of departure from officer/employee role: February 28, 2025.
- Murphy will continue to serve as a member of the Board of Directors.
TriSalus Life Sciences, Inc. has closed the 'Second Tranche' of its existing credit facility with OrbiMed Royalty & Credit Opportunities IV, LP, resulting in a $10 million cash infusion. As part of this transaction, the company issued warrants to purchase 91,263 shares of common stock at an exercise price of $5.4787 per share.
🚩 Red Flags
- Issuance of warrants at an exercise price ($5.4787) that may be dilutive to existing shareholders.
- The availability of future tranches is contingent upon the company satisfying 'certain revenue requirements,' indicating a performance-based funding structure common in high-risk micro-caps.
📋 Key Facts
- Closed Second Tranche of a senior secured credit facility on February 18, 2025.
- Borrower (TriSalus Operating Life Sciences, Inc.) received $10 million in proceeds.
- The loan matures on April 30, 2029.
- Issued warrants to purchase 91,263 shares of common stock at an exercise price of $5.4787 per share.
- Warrants have a term of 7 years from the issuance date (expiring February 2032).
- The facility includes a remaining Third Tranche of up to $15 million available by December 31, 2025, subject to revenue requirements.
TriSalus Life Sciences, Inc. announced a requested drawdown under its existing Credit Agreement with OrbiMed on February 3, 2025. This indicates the company is accessing available capital from its lender to bolster liquidity.
🚩 Red Flags
- Requesting a drawdown often indicates immediate liquidity needs or a desire to extend cash runway in the micro-cap biotech sector.
📋 Key Facts
- The company has requested a drawdown of funds under its current Credit Agreement.
- The lender for the credit facility is OrbiMed, a healthcare investment firm.
- The announcement was made via press release on February 3, 2025.
TriSalus Life Sciences, Inc. announced the expansion of its Board of Directors to 11 members with the appointment of two new directors, William Valle and Gary Gordon.
📋 Key Facts
- Board size increased to 11 directors on January 29, 2025.
- William Valle appointed as Class I director; term expires at 2027 annual meeting.
- Gary Gordon appointed as Class III director; term expires at 2026 annual meeting.
- Both directors to receive $50,000 annual cash retainer plus stock options (35,000 shares for Valle and 6,250 pro-rated shares for Gordon).
- William Valle appointed to the Audit Committee and Compensation Committee.
- Gary Gordon appointed to the Science and Technology Committee.
TriSalus Life Sciences announced the release of its preliminary unaudited financial results for the fiscal year and quarter ended December 31, 2024. The filing serves as a formal notice that earnings data was released via press release on January 23, 2025.
📋 Key Facts
- Preliminary unaudited financial results were announced for the period ending December 31, 2024.
- The announcement was made via a press release (Exhibit 99.1) on January 23, 2025.
- Company is classified as an 'Emerging Growth Company'.
- Trading symbols involved are TLSI (Common Stock) and TLSIW (Warrants).
TriSalus Life Sciences announced a leadership transition effective January 6, 2025. Sean Murphy is stepping down as CFO to become Chief Manufacturing, Strategy and Business Development Officer, while James Young is being promoted from SVP of Investor Relations to CFO.
🚩 Red Flags
- Executive turnover in the CFO role (though presented as a transition/promotion rather than a departure).
📋 Key Facts
- Effective Jan 6, 2025: James Young appointed CFO, Secretary, Treasurer, and principal financial officer.
- Effective Jan 6, 2025: Sean Murphy transitioned to Chief Manufacturing, Strategy and Business Development Officer; remains on the Board.
- James Young's new compensation includes a $420,000 base salary and a target performance bonus of up to 50% of base salary.
- Sean Murphy's annual base salary adjusted to $450,000.
- The Company implemented a 'Salary Investment Program' where executives can trade base salary for RSUs; as of Dec 31, 2024, officers elected to invest an aggregate of $515,052.
TriSalus Life Sciences, Inc. issued an 8-K to provide a business update and announce financial results for the quarter ended September 30, 2024.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing business and financial updates.
- Company is classified as an emerging growth company.
TriSalus Life Sciences announced the immediate resignation of Board member Anil Singhal and the departure of Chief Medical Officer Steven Katz, M.D.
🚩 Red Flags
- Simultaneous departure of a Board member and the Chief Medical Officer (CMO) can signal internal shifts or strategic changes.
- Loss of key medical leadership (CMO) in a life sciences company is a significant operational risk.
📋 Key Facts
- Dr. Anil Singhal resigned from the Board, Compensation Committee, and Science and Technology Committee effective October 28, 2024.
- The company stated Dr. Singhal's resignation is not due to any disagreement regarding operations, policies, or practices.
- Chief Medical Officer Steven Katz, M.D., ceased employment with the Company effective October 29, 2024.
TriSalus Life Sciences, Inc. reported its Q2 2024 financial results and announced the outcomes of its 2024 Annual Meeting of Stockholders. The meeting resulted in the election of four Class I directors and the ratification of Grant Thornton LLP as the independent auditor.
📋 Key Facts
- Company released business update and Q2 2024 financial results on August 15, 2024.
- Held 2024 Annual Meeting of Stockholders on August 13, 2024.
- Four Class I directors elected: Anil Singhal, Kerry Hicks, Liselotte Hyveled, and Sean Murphy.
- Stockholders ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Aggregate voting power at record date (June 26, 2024) was 31,455,515 shares.
TriSalus Life Sciences completed a warrant exchange offer and consent solicitation on July 1, 2024. The company issued 2,110,366 shares of common stock in exchange for tendered warrants.
🚩 Red Flags
- Dilution: The issuance of over 2.1 million new shares via warrant exchange results in immediate dilution for existing common shareholders.
📋 Key Facts
- Closed an offer to exchange various classes of warrants (TLSIW, private placement warrants, and working capital warrants) for common stock.
- Exchange ratio: 0.3 shares of Common Stock for each Warrant tendered.
- Total shares issued upon closing: 2,110,366 shares of Common Stock.
- The offer was conducted pursuant to a Registration Statement on Form S-4 filed on May 24, 2024.
- Included a consent solicitation to amend the existing Warrant Agreement dated December 17, 2020.
TriSalus Life Sciences completed a warrant exchange offer and consent solicitation that resulted in the approval of an amendment for Public Warrants only. This amendment allows the company to force the conversion of remaining Public Warrants into common stock at a reduced ratio of 0.27 shares per warrant.
🚩 Red Flags
- Significant dilution: The company is forcing a conversion of warrants into common stock at a reduced ratio (0.27 vs 0.3).
- Fragmented capital structure: Failure to reach consent thresholds for Private Placement and Working Capital Warrants indicates significant friction with certain classes of security holders.
- Potential liquidity/capitalization pressure: The use of warrant exchanges and forced conversions is often a mechanism used by micro-cap companies to clean up their cap table or manage debt/equity obligations.
📋 Key Facts
- The Offer and Consent Solicitation expired on June 25, 2024.
- Public Warrants: 6,533,614 warrants (approx. 78.89%) were validly tendered for exchange at a ratio of 0.3 shares per warrant.
- Private Placement Warrants: 504,685 warrants (approx. 10.23%) were tendered; however, the required consent threshold was not met for this class.
- Working Capital Warrants: 0% were tendered and the consent threshold was not met.
- The approved Warrant Amendment allows the company to require Public Warrants to be converted into 0.27 shares of Common Stock (a 10% reduction from the exchange ratio).
- The Company has the right to force the exchange of all outstanding Public Warrants upon 15 days' notice.
TriSalus Life Sciences announced an offer to exchange various classes of outstanding warrants (Public, Private Placement, and Working Capital) for common stock at a ratio of 0.3 shares per warrant. The company is also seeking consent from warrant holders to amend the Warrant Agreement, which would allow them to force-exchange remaining warrants into common stock at a lower ratio of 0.27.
🚩 Red Flags
- Significant potential dilution of existing shareholders through the issuance of up to 4.26 million new shares.
- The proposed 'Warrant Amendment' allows the company to force-exchange warrants at a less favorable ratio (0.27 vs 0.3), which is punitive to warrant holders.
- Complexity of the multi-class consent requirement: Success depends on reaching majority thresholds across different classes of warrants.
📋 Key Facts
- Offer: Exchange Warrants for Common Stock at a ratio of 0.3 shares per warrant.
- Total potential dilution: Up to 4,264,532 shares of Common Stock.
- Consent Solicitation: Seeking to amend the Warrant Agreement to allow Company-option exchange at a 0.27 ratio (a 10% reduction in value compared to the Offer).
- Current Support: Parties representing ~34.8% of Public Warrants have already agreed to tender/consent via Tender and Support Agreements.
- Expiration Date: The offer is scheduled to expire at 11:59 p.m. ET on June 25, 2024.
TriSalus Life Sciences, Inc. issued an 8-K to provide a business update and announce financial results for the quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 15, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes a press release (Exhibit 99.1) containing business and financial updates.
- Company is an emerging growth company.
TriSalus Life Sciences, Inc. announced the appointment of Liselotte Hyveled to its Board of Directors on May 6, 2024. The appointment increases the board size to ten directors.
📋 Key Facts
- Liselotte Hyveled appointed as a Class I director effective May 6, 2024.
- Term expires at the 2024 annual meeting of stockholders.
- Annual cash retainer: $50,000 for board service plus $15,000 total for committee service (Nominating and Corporate Governance; Science and Technology).
- Equity compensation: Option to purchase 35,000 shares of common stock vesting over three years.
- Automatic annual option grants of 15,000 shares subject to continuous service.
TriSalus Life Sciences entered into a $50 million senior secured credit facility with OrbiMed Royalty & Credit Opportunities IV, LP. The deal includes an immediate $25 million draw and warrants issued to the lender as equity compensation.
🚩 Red Flags
- High interest rate structure (SOFR + 8.50% or minimum 12.5%).
- Equity warrants issued to the lender as part of the debt financing (potential dilution).
- Revenue-based repayment trigger: failure to meet TriNav® revenue targets triggers immediate monthly principal repayments.
- Significant restrictive covenants including limitations on incurring additional debt, making acquisitions, or paying dividends.
📋 Key Facts
- Entered into a five-year senior secured credit agreement on April 30, 2024.
- Total facility amount: up to $50 million (Initial $25M; Delayed Draw of $10M by June 30, 2025; and $15M by Dec 31, 2025).
- Interest rate: Higher of SOFR or 4.00% + 8.50% (totaling ~12.5%+ depending on SOFR).
- Borrower must maintain unrestricted cash/equivalents $\ge$ $5M before March 31, 2025, and $\ge$ $10M thereafter.
- Issued warrants to the lender for 130,805 shares (5% of initial commitment) at an exercise price of $9.5562 per share.
- The credit agreement includes a revenue-based repayment trigger: if TriNav® infusion system revenue targets are not met, monthly principal repayments become mandatory.
TriSalus Life Sciences dismissed KPMG LLP as its independent auditor and appointed Grant Thornton LLP. The dismissal follows a period where the company received going concern warnings due to recurring operating losses and multiple material weaknesses in internal controls.
🚩 Red Flags
- Auditor change combined with existing 'going concern' language
- Material weakness regarding accounting for Standby Equity Purchase Agreements
- Material weakness regarding business combination controls
- Material weakness regarding valuation of warrants and tranche rights/obligations
- Material weakness in equity management system data conversion
- Recurring operating losses necessitating additional funding
📋 Key Facts
- KPMG LLP was dismissed by the Audit Committee on April 12, 2024.
- Grant Thornton LLP (GT) has been engaged as the new independent auditor for fiscal year ending December 31, 2024.
- KPMG's previous audit reports included a 'going concern' paragraph due to recurring losses and the need for additional equity or debt.
- The company reported multiple material weaknesses in internal controls over financial reporting (ICFR) as of Dec 31, 2023.
TriSalus Life Sciences, Inc. issued a press release providing a business update and announcing financial results for the quarter and year ended December 31, 2023.
📋 Key Facts
- Report date: April 1, 2024
- Reporting period: Quarter and Year ended December 31, 2023
- The filing includes a business update and unaudited financial results via Exhibit 99.1
- Company is an emerging growth company
TriSalus Life Sciences released preliminary unaudited financial results for FY2023, reporting significant revenue growth driven by the TriNav® Infusion System. However, the company disclosed a limited cash runway, stating it expects to have sufficient liquidity only into the second quarter of 2024.
🚩 Red Flags
- Limited liquidity: Company expects cash to last only through Q2 2024, indicating an imminent need for capital raising (dilution risk).
- Preliminary data: Financials are unaudited and subject to final adjustments/closing procedures.
📋 Key Facts
- Q4 2023 preliminary revenue: ~$5.7 million (up ~77% YoY).
- Full year 2023 preliminary revenue: ~$18.5 million (up ~49% YoY).
- Gross margins improved to ~90% for Q4 and ~86% for FY2023.
- Cash and cash equivalents as of Dec 31, 2023: ~$11.8 million.
- Liquidity runway is projected only into the second quarter of 2024.
TriSalus Life Sciences, Inc. announced a stock option grant to its Chief Financial Officer, Sean Murphy, in recognition of his performance during 2023.
📋 Key Facts
- Grant Date: January 24, 2024
- Recipient: Sean Murphy (Chief Financial Officer)
- Instrument: Stock Option to purchase 125,000 shares of common stock
- Exercise Price: $9.28 per share
- Vesting Schedule: 25% on the one-year anniversary; remaining 75% in 36 equal monthly installments subject to continuous service
- Plan: 2023 Equity Incentive Plan
TriSalus Life Sciences, Inc. filed an 8-K to furnish an investor presentation containing preliminary sales information for the fiscal year ended December 31, 2023, and a business update.
📋 Key Facts
- The filing includes Exhibit 99.1: Investor Presentation dated January 2024.
- Presentation contains preliminary sales information for the year ended December 31, 2023.
- Presentation provides a general business and product update to investors and analysts.